Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Wako Life Sciences Receives AACC Award

Published: Tuesday, February 04, 2014
Last Updated: Tuesday, February 04, 2014
Bookmark and Share
Dr. Shinji Satomura and Dr. Henry Wada receives the award for the uTASWako i30 Immunoanalyzer.

Dr. Shinji Satomura, President, and Dr. Henry Wada, CSO of Wako Life Sciences, Inc., received an award from the Northern California Section of AACC for the scientific and technology contribution to clinical chemistry achieved by the development of the uTASWako i30 Immunoanalyzer.

"Wako is happy to receive this award for the uTASWako i30 Immunoanalyzer which was the first application of Lab-on-a-Chip technology on an IVD instrument."

The uTASWako i30 has enabled miniaturization and integration of key analyzer processes for the sampling, mixing, separation and detection of serum biomarkers in a cost effective microfluidic chip.

The system uses immunochemical and electrophoretic techniques to achieve rapid, accurate, precise and sensitive assay results. The first test result is obtained in nine (9) minutes from starting the measurement; results thereafter are 2 minutes each.

As a bench-top automated instrument, the μTASWako i30 is designed for efficiency and ease-of-use in a clinical laboratory setting. With the features of automated calibration and quality control, the uTASWako i30 requires minimal setup time.

"We acknowledge the technical achievement of the team of Scientists and Engineers at Wako Life Sciences, Inc. and Wako Pure Chemical Industries, Ltd., who married the benefits of microfluidics with the requirements of the IVD market in order to bring this product to the clinical laboratory," said Henry Wada, CSO of Wako Life Sciences, Inc.

uTASWako i30 is currently available in the USA, Canada, Japan and Europe for the serum biomarkers lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) tests.

The AFP-L3 and DCP tests are intended for in vitro diagnostic use as an aid in the risk assessment of patients with chronic liver disease for development of hepatocellular carcinoma (HCC) in conjunction with other laboratory findings, imaging studies and clinical assessment.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Five New Breast Cancer Genes Found
Discovery of mutations paves the way for personalised treatment of breast cancer.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Magnetic Nanoparticles May Reveal Early Traces Of Cancer
Rice University students’ computer program aids MD Anderson diagnostic initiative .
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!